cGxP.wire https://validator.w3.org/feed/docs/rss2.html Mighty Therapeutics Wins $1M XPRIZE Healthspan Milestone Rigel Launches VEPPANU for ESR1-Mutated Breast Cancer Atrium Therapeutics Earns $15M BMS Milestone Payment Neuralytix Expands iD3 System for Spine Surgery Mendaera Reports 98% Success for Focalist System Zoetis Receives FDA EUA for Simparica Trio in Dogs Pfizer and Valneva Secure EMA Validation for Lyme Vaccine Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis Freenome Gains FDA Breakthrough Device Designation Bristol Myers Squibb Wins FDA Approval for ZENBEXUS Taiho Oncology Advances Zipalertinib in Phase 3 Trial Photys Therapeutics and Polymed Begin Phase 1 Trial of PHT-776 Eupraxia Reports Durable EoE Symptom Improvements With EP-104GI Summit Therapeutics Gains China Approval for Ivonescimab Sagimet Biosciences Secures FDA Clearance for Acne Phase 3 Trial Biomea Fusion Doses First Patient in Obesity OPAL Study ArkBio Advances AK0406 with China IND Approval Pharming Launches Joenja in Japan for APDS Patients Salus Scientific Advances Radiation Safety with AeroShield Cycle Pharmaceuticals Partners With Forma Life Sciences for CAVHANZA Supply Sumitomo Pharma America Doses First Patient With DSP-3077 Aurisco Pharmaceutical Passes USFDA Inspection for Oligos Elevation Spine Receives FDA Clearance for Saber-XA PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months Propanc Biopharma Advances PRP as a Novel Approach for RAS-Driven Cancers Tasman Therapeutics Advances R-107 with Osmind Partnership Natera, Inc. and Kupando Therapeutics Launch Phase 1 Study to Monitor ctDNA in Advanced Skin Cancers Mapi Pharma Advances Once-Monthly Cariprazine Depot After Positive Phase I/IIa Results Bridge to Life Raises $110M to Expand Organ Perfusion Eli Lilly Escalates Fight Against Illegal Retatrutide Market Senhwa Advances CX-5461 in Photoimmunotherapy Research Belite Bio Wins FDA Priority Review for Tinlarebant NDA Mereo BioPharma Advances Alvelestat Toward Phase 3 Trial Autonomix Medical Completes GLP Study for FDA Submission Egg Medical Gains Patent Advantage After Rampart Appeal Ends Definium Therapeutics Reports Positive Phase 3 GAD Results Rhythm Pharmaceuticals Expands IMCIVREE Authorization in UK Boulevard Bio Launches with $65M to Advance Immunology Dark Horse Consulting Expands China Cell Therapy Practice Alterity Expands ATH434 Potential in Neurodegenerative Disease Teva Earns Investment-Grade Rating as Growth Strategy Advances Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy Bracco Gains FDA Clearance for VueJect Cardiac Imaging System LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer Alfasigma to Acquire Nordic Pharma in European M&A Deal Can-Fite Advances Phase III Programs With FDA and EMA Status Novonesis Launches Optiva® Triticum for Pasta Production Aligos Therapeutics Starts Phase 1 Study of ALG-170675 Belenos Biosciences Reports Positive Phase 2 BEL512 Results.